See more : Enovis Corporation (0I1B.L) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Barclays PLC (BCY.DE) Income Statement Analysis – Financial Results
- AstraZeneca Pharma India Limited (ASTRAZEN.BO) Income Statement Analysis – Financial Results
- Restaurant Brands International Inc. (0VFA.L) Income Statement Analysis – Financial Results
- Alphabet Inc. (GOOG.NE) Income Statement Analysis – Financial Results
- TraceSafe Inc. (TSF.CN) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNA)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
| General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
| Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
| EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
| Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
| Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
| Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperoxaluria (EH) -- -- Completed Dosing of Subjects...
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that...
Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow
The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this event..
Contrasting Cellectis (NASDAQ:CLLS) & Allena Pharmaceuticals (NASDAQ:ALNA)
Allena Pharmaceuticals (NASDAQ:ALNA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation. Valuation...
Allena Pharmaceuticals (NASDAQ:ALNA) and Allogene Therapeutics (NASDAQ:ALLO) Critical Comparison
Allena Pharmaceuticals (NASDAQ:ALNA) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Profitability...
Allena Pharmaceuticals (ALNA) Gets a Buy Rating from B.Riley FBR
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Allena Pharmaceuticals (ALNA), with a price target of $4.00. The
B.Riley FBR Maintains Their Buy Rating on Allena Pharmaceuticals (ALNA)
In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Allena Pharmaceuticals (ALNA), with a price target of $7.00.
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced...
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...
Source: https://incomestatements.info
Category: Stock Reports